InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Insider track record
CFODisclosed buys
1
Disclosed sells
0
T+90 hit rate
100%
T+90 mean return
+85.2%
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the detailed record of transactions filed by Reine Allan, Chief Financial Officer. Officer active across 2 companies, notably Foghorn Therapeutics Inc.. In total, 3 filings have been logged. Split: 1 buy · 0 sell. Total volume traded: €130k. Activity tracked since 9 August 2021. The latest transaction was disclosed on 21 May 2025 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Declarations3 total
125,000 shares@ US$1.1772100.0% of flowCommon StockSEC:0001894562-25-000026:0
Ideal exit: 15 Feb 2026 (T+270)
26,892 shares@ US$3.720.028% mcap50.0% of flowCommon StockSEC:0001562180-21-005284:0
26,892 shares@ US$3.7250.0% of flowCommon StockSEC:0001562180-21-005284
3 of 3 declarations
About Reine Allan
Allan Reine is the Chief Financial Officer at Foghorn Therapeutics Inc. He is responsible for financial management and strategic planning. Allan plays a vital role in optimizing financial resources and achieving the company's objectives.
